Sistemsko zdravljenje napredovalega medularnega karcinoma ščitnice
Systemic treatment of advanced medullary thyroid carcinoma

  • Cvetka Grašič-Kuhar Onkološki inštitut, Ljubljana
Keywords: medullary thyroid cancer, thyroid cancer, systemic treatment, advanced cancer, medullary thyroid carcinoma

Abstract

Medularni karcinom ščitnice nastane iz nevroendokrinih celic ščitnice, ki izločajo kalcitonin. Kalcitonin je specifičen marker medularnega raka ščitnice. Pri lokalno napredovalem ali metastaskem medularnem raku ščitnice ob simptomtskem progresu prihaja v poštev zdravljenje s tirozin kinaznimi inhibitorji. Registrirani substanci sta vandetanib in cabozantinib, učinkoviti pa sta tudi sorafenib in sunitinib. Izbira zdravljenja je individualizirana glede na breme bolezni in spremljajoče bolezni. Zelo pomembno je tudi podporno (na simptome usmerjeno) zdravljenje. ; slv - slovenski


Abstract (Eng)

Medullary thyroid carcinoma originates from neuroendocrine cells of the thyroid which secrete calcitonin. Calcitonin is a specific marker for medullary thyroid cancer. Therapy with tyrosine kinase inhibitors can be applied to treat locally advanced or metastatic medullary thyroid cancer with progressing symptoms. Registered substances used are vandetanib and cabozantinib, and sorafenib and sunitinib are also effective. Treatment is determined individually based on the burden of the cancer and secondary diseases. Supportive treatment (targeted at the symptoms) is also very important.

Published
2016-06-15
How to Cite
Grašič-Kuhar, C. (2016). Systemic treatment of advanced medullary thyroid carcinoma. Onkologija : A Medical-Scientific Journal, 20(1), 4-6. Retrieved from https://revijaonkologija.si/Onkologija/article/view/66
Section
Review Article
Page
4-6